Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced a company update presentation scheduled for March 15, 2022, at 10:00 AM Eastern Time during the Oppenheimer 32nd Annual Healthcare Conference. The event will be webcast live, with an archive available for 30 days afterward. Interested parties can access the webcast link via Tandem's Investor Center website. Tandem specializes in innovative insulin delivery systems, including the t:slim X2 insulin pump, designed to enhance the lives of individuals with diabetes.

Tandem Diabetes Care reported robust financial performance for 2021, achieving a 41% increase in sales to $702.8 million. Worldwide pump shipments rose by 41% to 128,312 pumps, with a gross margin of 54%. The company posted a net income of $15.6 million, a turnaround from a $34.4 million loss in 2020. For 2022, Tandem projects sales between $845 million and $860 million, indicating 20% to 22% annual growth. The guidance supports continued investment in innovation and operational improvements.

Tandem Diabetes Care announces FDA clearance for the t:connect mobile app, the first smartphone application allowing bolus insulin delivery via both iOS and Android. This update provides users of the t:slim X2 insulin pump the convenience of programming and canceling bolus requests using their smartphones. Available for free as a software update to existing users, the feature will roll out in limited phases starting in spring. The app enhances diabetes management by displaying glucose trends and pump data securely.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will provide an update at two virtual investor conferences. The first is Citi’s 2022 Virtual Healthcare Conference on February 24, 2022, at 11:00am ET, followed by Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 2:50pm ET. Both presentations will be webcast live, with archives available for 30 days on Tandem's Investor Center website. Tandem is focused on enhancing diabetes care through innovative products like the t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring.

Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.

Tandem Diabetes Care announced key management appointments to enhance its leadership team for future growth. Rick Carpenter joins as Chief Technical Officer, bringing over 30 years of engineering experience. Libba Sapitsky becomes Senior Vice President of Customer Care, with extensive background in customer service operations. Rizwan Pervez is appointed Senior Vice President for Quality and Regulatory, having over 20 years in compliance leadership. These roles aim to support product expansion and pipeline execution as Tandem continues its mission to improve diabetes care.

Tandem Diabetes Care (NASDAQ: TNDM) will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 2, 2021. A pre-recorded fireside chat featuring CEO John Sheridan and CFO Leigh Vosseller will be available starting November 22, 2021, at 10:00 AM ET. Investors can access the chat on the Tandem Diabetes Investor Center website under 'Events & Presentations.'

Tandem Diabetes is committed to enhancing diabetes management through innovative solutions, highlighted by its flagship t:slim X2™ insulin pump.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported strong Q3 2021 results, with pump shipments up 43% and sales increasing 45% to $179.6 million. Gross profit rose 48% to $96.7 million, while net income shifted to $5.8 million from a loss in 2020. The company raised its 2021 sales guidance to $685-$695 million, reflecting a growth of 37-39%. International sales soared by 189%, and gross margin improved to 54%. Cash reserves reached $595 million, indicating robust liquidity.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced management will present company updates at two upcoming virtual investor conferences. The first is on November 9, 2021, at 12:10 PM ET during the Credit Suisse 30th Annual Virtual Healthcare Conference, followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 4:00 PM ET. Both presentations will be webcast live, with recordings available for 30 days afterward. Interested parties can access the live and archive webcasts on Tandem's Investor Center website.